Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-10-2017 | Retinal Disorders

Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study

Authors: Irini Chatziralli, George Theodossiadis, Stamatina A. Kabanarou, Efstratios Parikakis, Tina Xirou, Panagiotis Mitropoulos, Panagiotis Theodossiadis

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2017

Abstract

Purpose

To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

Methods

Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups.

Results

At month 12, there was no statistically significant difference in BCVA and CST change between the two groups. However, there was recurrence in ME at month 5 in the dexamethasone group.

Conclusions

Both ranibizumab and dexamethasone implant were found to be safe and effective at the 12-month follow-up in patients with ME secondary to CRVO. Since there was a recurrence in ME at month 5 in the dexamethasone group, we suggested that intravitreal injection of dexamethasone implant should be potentially administered sooner than 6 months.

Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease Consortium (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319CrossRefPubMedPubMedCentral

Yau JW, Lee P, Wong TY, Best J, Jenkins A (2008) Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 38:904–910CrossRefPubMed

Deobhakta A, Chang LK (2013) Inflammation in retinal vein occlusion. Int J Inflam 2013:438412CrossRefPubMedPubMedCentral

Noma H, Funatsu H, Mimura T, Harino S, Hori S (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116:87–93CrossRefPubMed

McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117:1113–1123CrossRefPubMed

Chatziralli I, Nicholson L, Sivaprasad S, Hykin P (2015) Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials. Expert Opin Biol Ther 15:1685–1697CrossRefPubMed

Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRefPubMed

Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809CrossRefPubMed

Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A; RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219.

10.

Farinha C, Marques JP, Almeida E, Baltar A, Santos AR, Melo P, Costa M, Figueira J, Cachulo ML, Pires I, Silva R (2015) Treatment of retinal vein occlusion with Ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res 55:10–18CrossRefPubMed

11.

Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80–86CrossRefPubMed

12.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146CrossRefPubMed

13.

Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Ozurdex GENEVA Study Group (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453–2560CrossRefPubMed

14.

Maggio E, Polito A, Guerriero M, Pertile G (2014) Intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion: 12-month follow-up and prognostic factors. Ophthalmologica 232:207–215CrossRefPubMed

15.

Ferrini W, Ambresin A (2013) Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting. Klin Monatsbl Augenheilkd 230:423–426CrossRefPubMed

16.

Bezatis A, Spital G, Höhn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up -- the SOLO study. Acta Ophthalmol 91:e340–e347CrossRefPubMed

17.

Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO, COMRADE-C Study Group (2016) Clinical efficacy and safety of Ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol 169:258–267CrossRefPubMed

18.

Chiquet C, Dupuy C, Bron AM, Aptel F, Straub M, Isaico R, Romanet JP, Creuzot-Garcher C (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol 253:2095–2102CrossRefPubMed

19.

Mayer WJ, Hadjigoli A, Wolf A, Herold T, Haritoglou C (2015) Comparison of intravitreal dexamethasone implant versus intravitreal Ranibizumab as a first-line treatment of macular Oedema due to retinal vein occlusion. Klin Monatsbl Augenheilkd 232:1289–1296CrossRefPubMed

20.

Gado AS, Macky TA (2014) Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Exp Ophthalmol 42:650–655CrossRefPubMed

Title: Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study
Authors: Irini Chatziralli
George Theodossiadis
Stamatina A. Kabanarou
Efstratios Parikakis
Tina Xirou
Panagiotis Mitropoulos
Panagiotis Theodossiadis
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3719-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2017

Refining Coats’ disease by ultra-widefield imaging and optical coherence tomography angiography

Retinal VEGF levels correlate with ocular circulation measured by a laser speckle-micro system in an oxygen-induced retinopathy rat model

Characteristics of retinal vessels in surgically closed macular hole: an optical coherence tomography angiography study

Pre-papillary vitreous opacities associated with Behçet’s disease: a case series and review of the literature

Post-hypoxic constriction of retinal arterioles is impaired during nitric oxide and cyclo-oxygenase inhibition and in diabetic patients without retinopathy

Ganglion cell layer segmentation and the two-flash multifocal electroretinogram improve structure function analysis in early glaucoma